Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.

Molecular diagnosis : a journal devoted to the understanding of human disease through the clinical application of molecular biology - 1 Dec 1999

Iyer L

Abstract excerpt

Pharmacogenetics has emerged as a novel and challenging area of interest in oncology. Cancer chemotherapy is characterized by major intersubject variability in tumor responses and host toxicity. This variation may be caused by genetic differences in the enzymes involved in the metabolism of anticancer agents. Anticancer agents, such as 6-mercaptopurine, 5-fluorouracil, and irinotecan, have a narrow therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Genetic Variation

Share to Glucuronosyltransferase

Share to Methyltransferases

Share to Oxidoreductases

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 10671643
DOI: 10.1016/s1084-8592(99)80009-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.PMID 10671643Read ↗

Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.Semantic proximity Read ↗

Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.Semantic proximity Read ↗

Advances and challenges in hereditary cancer pharmacogenetics.Semantic proximity Read ↗

Update on pharmacogenetics in cancer chemotherapy.Semantic proximity Read ↗

Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Semantic proximity Read ↗

Part 3: Pharmacogenetic variability in phase II anticancer drug metabolism.Semantic proximity Read ↗

[Pharmacogenetics of anticancer drugs].Semantic proximity Read ↗

Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsSemantic proximity Read ↗

Pharmacogenetics: a tool for individualizing antineoplastic therapy.Semantic proximity Read ↗

Clinical applicability of sequence variations in genes related to drug metabolism.Semantic proximity Read ↗

Cancer pharmacogenomics: SNPs, chips, and the individual patient.Semantic proximity Read ↗

Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.